Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
AstraZeneca announces subgroup analysis from FALCON trial comparing FASLODEX® (fulvestrant) to ARIMIDEX® (anastrozole)
Subset of patients with non-visceral disease may show increased sensitivity to FASLODEX in 1st line therapy of advanced breast cancer
AstraZeneca today announced results from a pre-specified subgroup analysis of the positive Phase III FALCON trial suggesting that treatment effects in terms of progression-free survival (PFS) were largely consistent across the subgroups analyzed with some possible exceptions, including patients with non-visceral disease.
TAGRISSO® (osimertinib) demonstrates superiority over chemotherapy in EGFR T790m mutation-positive non-small cell lung cancer
First randomized Phase III trial (AURA3) of TAGRISSO against chemotherapy
TAGRISSO reduced risk of disease progression by 70% and improved progression-free survival (PFS) by almost six months
Patients with central nervous system (CNS) metastases achieved consistent results with the overall patient population in pre-specified exploratory subgroup analysis
Early data demonstrate clinical activity of acalabrutinib in difficult-to-treat chronic lymphocytic leukemia
Phase I/II trial findings add to growing body of data on acalabrutinib clinical profile
AstraZeneca and its hematology Center of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat forms of chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults.
AstraZeneca announces study results show SYMBICORT improves lung function in pediatric asthma patients
Results from the international, multicenter ChildHood Asthma Safety and Efficacy (CHASE) 3 Phase III study showed that SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms significantly improved lung function in pediatric patients between 6 to <12 years of age with asthma versus budesonide 80 micrograms, demonstrating its appropriateness as step-up therapy in this patient population.
Latest AZ&You Blog Articles
The Power of Us: Employees’ Community Impact in 2016
AstraZeneca has a long history of community service and a strong commitment to making a meaningful difference for patients and communities beyond our medicines through our corporate responsibility activities. In addition to our corporate efforts, our Power of Us program empowers employees to give back in two ways: by providing paid time off to volunteer with nonprofit organizations of their choice, as well as by matching their charitable donations.
Stigma, Genetics and Hope: 11 Years with Lung Cancer
In 2005, Melissa Crouse was diagnosed with lung cancer and given three to five years to live. Eleven years later, Melissa continues to manage her disease while giving back to the lung cancer community and getting the most out of life. Melissa shares her perspective on living with lung cancer, understanding the importance of biomarkers, and remaining hopeful.
What Does the New CancerLinQ Discovery Initiative Mean for the Future of Patient Care?
By Kevin Fitzpatrick, CEO, CancerLinQ LLC
This is an exciting time in the field of oncology—a time of rapid discovery, learning and new treatments to fight this terrible disease, as we work to provide patients with greater hope. Imagine taking these daily learnings and aggregating them in one accessible place while simultaneously creating a learning platform that medical oncologists can use to help improve patient care.
Personalized Healthcare: What It Means and Why It Matters
When it comes to cancer treatment, one size does not fit all. Of the estimated 1.6 million Americans who will be diagnosed with cancer in 2016, no two will be exactly the same. More and more, we’re hearing (and using) buzzwords to this effect: Personalized healthcare. Precision medicine. Targeted therapy.
What Getting ON IT Means to Me for American Diabetes Month®
By Dr. Phil McGraw
As someone who has lived with type 2 diabetes for more than 25 years, I understand the day-to-day issues that accompany managing a lifelong disease. It’s important to me to amplify the conversation around these challenges that people living with type 2 diabetes experience.
How the Type 2 Diabetes Patient Community is Unifying their Voice Online
While online conversations about diabetes are on the rise and people with diabetes have cultivated the Diabetes Online Community (#DOC) as a way to connect with one another, those living with type 2 diabetes seem to play a less active part in the dialogue. To help strengthen and elevate the voices of type 2 diabetes advocates, AstraZeneca recently hosted members of the type 2 community for DiabetesLinkup: In It 2gether.
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.